StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Leerink Partners Remains Bullish as Teva Pharma (TEVA) Awaits IPR Ruling
August 15, 2016 2:00 PM
Leerink Partners reiterated an Outperform rating and $66.00 price target on Teva Pharma (NYSE: TEVA) ahead of an IPR ruling ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Next Articles
Blue Ridge Capital's 13F Shows New Stake in Och-Ziff (OZM), Increase in Chesapeake (CHK), Reduced Teva (TEVA) (more...)
August 15, 2016 11:41 AM
Mylan (MYL) Loses Bid to Challenge 4th Capoxone Patent Expiring 2030 - Bloomberg (TEVA)
August 15, 2016 10:59 AM
Teva Pharma (TEVA): Upcoming Catalysts
August 15, 2016 8:31 AM
Guggenheim Reiterates Buy on Teva Pharma (TEVA) Following AGN Deal
August 15, 2016 7:21 AM
Teva Pharma (TEVA)
August 15, 2016 4:53 AM
